OR-USB-IF
27.5.2021 00:02:07 CEST | Business Wire | Press release
The USB Promoter Group today announced the release of the USB Power Delivery (USB PD) Revision 3.1 specification, a major update to enable delivering up to 240W of power over the USB Type-C® cable and connector. Prior to this update, USB PD was limited to 100W via a solution based on 20V using USB Type-C cables rated at 5A. The USB Type-C specification has also been updated with Release 2.1 to define 240W cable requirements, and with the updated USB PD protocol and power supply definition, this extends the applicability of USB PD to a large number of applications where 100W wasn’t adequate.
The new USB PD architecture defines a much more stringent power negotiation protocol that helps to ensure that access to and use of this higher power capability can be done safely. It should be noted that safety requirements for products that use power in the range of 100 – 240W are also more stringent than lower power products and are defined by the applicable safety specifications dictated by the regulations for each country where the products will be sold.
“With the new capabilities of USB Power Delivery 3.1, we now enable higher power products such as larger notebook PCs to shift from traditional power connectors to USB Type-C,” said Brad Saunders, USB Promoter Group Chairman. “We also anticipate a wider range of product application developers outside of the traditional USB ecosystem to now consider standardizing on USB Type-C with USB PD power their power needs.”
Key characteristics of the USB PD 3.1 specification include:
- A choice of three new fixed voltages: 28V (above 100W), 36V (above 140W) and 48V (above 180W) joining previously defined 5V, 9V, 15V and 20V fixed voltages.
- A new adjustable voltage mode enabling a range from 15V to one of three maximum voltages (28V, 36V, or 48V) depending on the available power allowing the device being powered to request specific voltages to a 100 mV resolution.
USB Developer Days 2021, in the second half of this year, will include detailed technical training covering the updated USB PD and USB Type-C specifications.
This update is part of the USB performance roadmap and is specifically targeted to developers at this time. Branding and marketing guidelines are being established and will include a new cable labeling solution to inform users of the power capability supported by Certified USB Type-C cables.
“Always responsive to the market’s need for a higher-power, truly universal bus connector, the USB Promoter Group has again been quick to recognize and adapt its specifications for charging capability to anticipate customer requirements, potentially creating new markets for USB Power Delivery. ST, as an active member of the USB Promoter Group, with its strong company legacy of cooperation, technical expertise, and product reliability, will continue to provide high-quality, optimized semiconductor solutions,” said Matteo Lo-Presti, Executive Vice President, Analog, Sub-Group General Manager, Analog MEMS, and Sensors Group, STMicroelectronics.
“The 3.1 revision to the USB Power Delivery specification, which includes the capability to provide up to 48 V and 240 W of power, will help enable additional design opportunities for current and new users of USB Type-C technology,” said Deric Waters, senior member of technical staff at Texas Instruments.
About the USB Promoter Group
The USB Promoter Group, comprised of Apple Inc., Hewlett-Packard Inc., Intel Corporation, Microsoft Corporation, Renesas Electronics Corporation, STMicroelectronics, and Texas Instruments, continues to develop the USB family of specifications to meet the market needs for increased functionality and performance of USB solutions. Additionally, the USB Promoter Group develops specification addendums (USB Power Delivery, USB Type-C®, and others) to extend or adapt its specifications to support more platform types or use cases where adopting USB technology will be beneficial in delivering a more ubiquitous, richer user experience.
About the USB-IF
The non-profit USB Implementers Forum, Inc. was formed to provide a support organization and forum for the advancement and adoption of USB technology as defined in the USB specifications. The USB-IF facilitates the development of high-quality compatible USB devices through its logo and compliance program, and promotes the benefits of USB and the quality of products that have passed compliance testing. Further information, including postings of the most recent product and technology announcements, is available by visiting the USB-IF website at www.usb.org .
USB Type-C® and USB-C® are registered trademarks of USB Implementers Forum.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526006131/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces filing of registration statement for proposed initial public offering8.6.2026 13:20:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, announces today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP Paribas, Mizuho, Societe Generale, Crédit Agricole CIB, IMI – Intesa Sanpaolo, UniCredit, and Banca Akros – Gruppo Banco BPM are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other condit
Xsolla to Attend SuperReturn International 2026 to Advance Strategic Partnerships and Expand Its Presence in Global Private Capital8.6.2026 13:15:00 CEST | Press release
Xsolla Heads to Berlin to Advance and Foster Private Capital Relationships, Advance and Engage Senior Investors Across the Private Capital Ecosystem Xsolla, a global leader in video game commerce, today announced its participation in SuperReturn International 2026, taking place June 8–12 at the InterContinental Berlin. Uniting more than 6,000 senior attendees, including 2,000+ LPs and 3,000 GPs, SuperReturn International is widely recognized as the capital of private capital with the best investment opportunities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607269536/en/ Graphic: Xsolla The video game industry has matured into one of the largest and most resilient segments of the global entertainment economy, outpacing film and music combined, driving continuous growth through shifting market cycles. Yet the infrastructure powering how games are sold, monetized, and distributed worldwide remains under-examined
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom